Skip to content
10-Q

Quarterly Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-26-053980

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 31.37M sh
Shares Diluted Q1 2026 · Mar 31, 2026 31.24M sh
Shares Diluted Q1 2026 · Mar 31, 2025 31.2M sh
Capex Q1 2026 · Mar 31, 2026 $2K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.87M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.57M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $42.13M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $48M
Stockholders Equity Q1 2026 · Mar 31, 2026 $2.3M
Stockholders Equity Q1 2026 · Dec 31, 2025 $7.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 $25.69M
Stockholders Equity Q1 2026 · Dec 31, 2024 $32.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.35M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $43.13M
Total Liabilities Q1 2026 · Dec 31, 2025 $43.94M
Current Assets Q1 2026 · Mar 31, 2026 $43.26M
Current Assets Q1 2026 · Dec 31, 2025 $49.38M
Total Assets Q1 2026 · Mar 31, 2026 $45.44M
Total Assets Q1 2026 · Dec 31, 2025 $51.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.18
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.51
Eps Basic Q1 2026 · Mar 31, 2026 −$0.18
Eps Basic Q1 2026 · Mar 31, 2025 −$0.51
Sga Expense Q1 2026 · Mar 31, 2026 $1.7M
Sga Expense Q1 2026 · Mar 31, 2025 $8.94M
Rd Expense Q1 2026 · Mar 31, 2026 $4.2M
Rd Expense Q1 2026 · Mar 31, 2025 $7.7M
Net Income Q1 2026 · Mar 31, 2026 −$5.52M
Net Income Q1 2026 · Mar 31, 2025 −$15.94M
Operating Income Q1 2026 · Mar 31, 2026 −$5.9M
Operating Income Q1 2026 · Mar 31, 2025 −$16.64M